Home > Insider Trading > Filing (0000899243-22-034897)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1466301	Clovis Oncology Inc.	CLVS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1268304	C Gillian Ivers-Read	C/O Clovis Oncology, Inc. 5500 Flatiron Parkway, Suite 100 Boulder CO 80301	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-11-01	3,749	$0.00	292,668	No	4	M	Direct
Common Stock	Disposition	2022-11-02	1,675	$0.98	290,993	No	4	S	Direct
Common Stock	Acquisiton	2022-11-01	4,625	$0.00	295,618	No	4	M	Direct
Common Stock	Disposition	2022-11-02	2,006	$0.98	293,612	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2022-11-01	3,749	$0.00	3,749	$0.00
Common Stock	Restricted Stock Units	Disposition	2022-11-01	4,625	$0.00	4,625	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,750			No	4	M	Direct
23,125			No	4	M	Direct

Footnotes

Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
This transaction was executed in multiple trades at prices ranging from $0.9621 to $0.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.